Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tina Young Poussaint, M.D.

Co-Author

This page shows the publications co-authored by Tina Poussaint and Katherine Warren.
Connection Strength

1.002
  1. Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020 06; 21(6):e317-e329.
    View in: PubMed
    Score: 0.219
  2. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro Oncol. 2018 01 10; 20(1):13-23.
    View in: PubMed
    Score: 0.186
  3. Response to Harreld re: "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee". Neuro Oncol. 2018 01 10; 20(1):144-145.
    View in: PubMed
    Score: 0.186
  4. Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group. Pediatr Blood Cancer. 2013 Sep; 60(9):1397-401.
    View in: PubMed
    Score: 0.134
  5. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neurooncol. 2012 Feb; 106(3):643-9.
    View in: PubMed
    Score: 0.120
  6. Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors. Neuro Oncol. 2022 02 01; 24(2):289-299.
    View in: PubMed
    Score: 0.062
  7. Corrigendum to: Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors. Neuro Oncol. 2021 Dec 01; 23(12):2124.
    View in: PubMed
    Score: 0.061
  8. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). Cancer. 2013 Dec 01; 119(23):4180-7.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.